FDA Issues CRL for Telix’s Breakthrough Kidney Cancer Imaging Agent TLX250-CDx Over Manufacturing Concerns
The FDA has issued a Complete Response Letter for TLX250-CDx (Zircaix), rejecting the biologics license application for this breakthrough therapy-designated PET imaging agent due to...
